ProQR Therapeutics N.V.
corporate_fare Company Profile
ProQR Therapeutics N.V. (NASDAQ:PRQR) is a publicly traded company in the Life Sciences sector. Wiseek monitors PRQR SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.
Recent high-impact activity:
- ProQR CEO Daniel de Boer invests $261K in open-market purchase
- ProQR Therapeutics CEO Buys $238.5K in Open Market Shares
- Major Shareholder Van Herk Investments' Stake Diluted to 10.9% Post-Offering
- Eli Lilly Invests $9.2M in ProQR as Biotech Raises $50M
- ProQR Raises $59.2M at Premium, Eli Lilly Maintains Stake
Financial Snapshot
Dilution Risk
Low riskFiling-implied dilution signals for PRQR, detected from its recent SEC filings · based on capital-structure filings through 2026-07-15.
Capital Raise Finalized · Significant Dilution
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →
Insider Transactions
PRQR files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.